1.	Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-020, NCT00689936
2.	Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
3.	Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
4.	Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 0 to 55 Sponsor: Other Protocol IDs: 8717, NCT00673114
5.	A Phase II Study of Umbilical Cord Blood Transplantation Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: UCBT001, NCT00676806
6.	T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 11300A, NCT00683046
7.	Phase II Study of Pre- and Post-Transplant Rituximab in Patients Undergoing Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory CD20+ B-Cell Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: FHCRC-2226.00, FHCRC-2226.00, IR-6884, NCT00867529
8.	Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MU9230, NCT00899353
9.	Phase II Pilot Study of Green Tea Catechin Extract (Polyphenon E) in Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WSU-2009-015, 2009-015, NCT00942422
10.	A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081001, NCT00585195
11.	Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
12.	Oral NRX 194204 in Patients With Refractory Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 0C-07-6, NCT00630760
13.	Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AP24534-07-101, NCT00660920
14.	Phase I Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 in Combination With Temsirolimus in Patients With Locally Advanced or Metastatic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: MDA-2007-0595, 2007-0595, 8109, NCT00678223
15.	Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 265-102, NCT00679133
16.	Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Phase: Phase I Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLI-107-08, MSKCC IRB #07-127, NCT00684008
17.	Pilot Study of Double Umbilical Cord Blood Stem Cell Transplantation in Patients With Hematologic Cancer or Other Diseases Phase: No phase specified Type: Treatment Status: Active Age: Under 70 Sponsor: NCI Protocol IDs: WSU-2006-059, WSU-112506MP2F, NCT00423826
18.	Study of Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: NU-06C2, NU-IRB-1398-031, NCT00424242, LILLY-NU-06C2
19.	Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations. Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Cell Saver 704.03, NCT00708513